Elevated Lp(a) independently identifies a high-risk calcific coronary phenotype beyond LDL-C levels, an intravascular ultrasound (IVUS) study carried out by Dr Yu Iemeura and colleagues at Saitama Medical Center, Kawagoe, Japan, has shown.
AstraZeneca has provided a sponsorship grant towards this independent programme.